Please ensure Javascript is enabled for purposes of website accessibility

Rockville-based EntreMed shows loss in fourth quarter

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing drugs for the treatment of cancer, reported a fourth-quarter net loss of $360, 430, or 2 cents per diluted share, versus net income of 1 million, or 6 cents per diluted share, for the prior-year period.

Revenue was $669,310 for the three months ended Dec. 31, 2012, compared to $1.9 million for the same period in 2011.

EntreMed attributed the fourth-quarter loss directly to declining royalties from Celgene Corp. on sales of Thalomid.

Celgene, of Summit, N.J., licensed Thalomid, a drug used to treat cancer that is related to thalidomide, in 1996 from EntreMed.